MX2011011960A - Peptidos penetradores de celulas. - Google Patents

Peptidos penetradores de celulas.

Info

Publication number
MX2011011960A
MX2011011960A MX2011011960A MX2011011960A MX2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A
Authority
MX
Mexico
Prior art keywords
cell membrane
acid sequence
amino acid
peptide
permeability
Prior art date
Application number
MX2011011960A
Other languages
English (en)
Inventor
Reiji Nishio
Mariko Morishita
Kozo Takayama
Nobuo Ida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2011011960A publication Critical patent/MX2011011960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un péptido penetrador de célula descrito en cualquiera de (A) a (D) que da permeabilidad a membrana celular y además capacidad de absorción transmucosa a una sustancia fisiológicamente activa: (A) un péptido que tiene la secuencia de aminoácidos representada por SEQ ID NO:1; (B) un péptido que tiene una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por SEQ ID NO:1 excepto que uno o varios aminoácidos básicos se sustituyen, se suprimen, se insertan y/o se adicionan, péptido que tiene permeabilidad en membrana celular; (C) un péptido que tiene una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por SEQ ID NO:1, excepto que de 1 a 5 aminoácidos se sustituyen, se suprimen, se insertan y/o se adicionan, cuyo péptido tiene, permeabilidad en membrana celular; (D) un péptido que tiene: una secuencia de aminoácidos representada por la secuencia inversa de cualquiera de (A) a (C); una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por la secuencia inversa de (A), excepto que uno o varios aminoácidos básicos se sustituyen, se suprimen, se insertan y/o se adicionan; o una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por la secuencia inversa de (A) excepto que de 1 a 5 aminoácidos se sustituyen, se suprimen, se insertar y/o adicionan; cuyo péptido tiene permeabilidad en membrana celular.
MX2011011960A 2009-05-20 2010-05-19 Peptidos penetradores de celulas. MX2011011960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009122096 2009-05-20
JP2010071774 2010-03-26
PCT/JP2010/058420 WO2010134537A1 (ja) 2009-05-20 2010-05-19 細胞膜透過性ペプチド

Publications (1)

Publication Number Publication Date
MX2011011960A true MX2011011960A (es) 2011-12-06

Family

ID=43126214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011960A MX2011011960A (es) 2009-05-20 2010-05-19 Peptidos penetradores de celulas.

Country Status (13)

Country Link
US (1) US8772449B2 (es)
EP (1) EP2433953B1 (es)
JP (1) JP5653214B2 (es)
KR (1) KR101783291B1 (es)
CN (1) CN102428096B (es)
AU (1) AU2010250452B2 (es)
BR (1) BRPI1008230B1 (es)
CA (1) CA2762551C (es)
ES (1) ES2546304T3 (es)
MX (1) MX2011011960A (es)
PL (1) PL2433953T3 (es)
RU (1) RU2548807C2 (es)
WO (1) WO2010134537A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法
EP3428181A3 (en) 2012-05-11 2019-02-20 KAEL-GemVax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
CN104507489B (zh) 2012-05-11 2016-07-13 杰姆维克斯&凯尔有限公司 用于预防和治疗类风湿性关节炎的组合物
EP2873678B8 (en) 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Conjugate comprising a cell-penetrating peptide and compositions comprising same
ES2758451T3 (es) 2012-09-19 2020-05-05 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
JP6059405B2 (ja) 2013-06-07 2017-01-11 ジェムバックス アンド カエル カンパニー，リミティド 癌の免疫学的治療に有用な生物学的マーカー
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
KR102166544B1 (ko) 2013-10-23 2020-10-16 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
WO2015076621A1 (ko) 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
KR102373603B1 (ko) 2014-04-11 2022-03-14 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
ES2880473T5 (es) 2015-01-30 2024-05-09 Univ California Suministro de proteínas en células hematopoyéticas primarias
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
RU2712623C2 (ru) 2015-03-31 2020-01-30 Илдонг Фарм. Ко., Лтд. Фармацевтическая композиция для предотвращения и лечения заболеваний глаз, содержащая в качестве активного ингредиента белок слияния, в котором слиты проникающий в ткань пептид и препарат против фактора роста эндотелия сосудов
KR20180004752A (ko) 2015-05-26 2018-01-12 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017127567A1 (en) * 2016-01-19 2017-07-27 Genebiologics, Llc Production of arginine-rich proteins and use as a fertilizer and germination enhancer
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EP3556766A4 (en) * 2016-12-16 2020-07-22 Avixgen Inc. CYTOPLASMATIC TRANSDUCTION PEPTIDE AND INTRACELLULAR MESSENGER WITH IT
JP2019099578A (ja) * 2017-12-06 2019-06-24 参天製薬株式会社 細胞膜透過性ペプチドを含有する眼科用医薬組成物
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
CA3093356A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109553659B (zh) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 一种细胞穿透肽及透皮干扰素
CN109575107B (zh) * 2018-11-26 2022-03-08 上海华新生物高技术有限公司 一种细胞穿透肽及可表达口服干扰素的双歧杆菌
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
EP4230223A1 (en) 2020-10-16 2023-08-23 Josho Gakuen Educational Foundation Composition
CN114805593A (zh) * 2021-01-19 2022-07-29 盛世泰研(广东)健康科技有限公司 一种具有穿膜功能的Penetratin-hSOD1及其制备方法与应用
KR20220157778A (ko) * 2021-05-21 2022-11-29 원큐어젠 주식회사 세포 투과성 펩타이드 및 글루카곤 유사 펩타이드-1 수용체 작용제를 포함하는 복합체
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656950B1 (en) 1992-08-21 1998-11-04 Biogen, Inc. Tat-derived transport polypeptides
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
ATE419273T1 (de) * 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
US7291594B2 (en) 2002-10-11 2007-11-06 Sanwa Kagaku Kenkyusho Co., Ltd. GLP-1 derivative and preparation thereof absorbable via mucous membrane
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
JP2005185271A (ja) * 2003-12-03 2005-07-14 Credia Japan:Kk 膜透過性ペプチド核酸
KR20080007425A (ko) * 2004-11-05 2008-01-21 팔링겐, 인코포레이티드 항체 유도된 세포막 손상
KR101585046B1 (ko) * 2008-02-28 2016-01-13 도레이 카부시키가이샤 경비 투여용 의약 조성물
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法

Also Published As

Publication number Publication date
US8772449B2 (en) 2014-07-08
ES2546304T3 (es) 2015-09-22
RU2548807C2 (ru) 2015-04-20
JP5653214B2 (ja) 2015-01-14
BRPI1008230B1 (pt) 2019-05-28
RU2011151877A (ru) 2013-06-27
AU2010250452B2 (en) 2014-06-05
CA2762551A1 (en) 2010-11-25
EP2433953B1 (en) 2015-07-08
US20120065124A1 (en) 2012-03-15
CN102428096A (zh) 2012-04-25
CA2762551C (en) 2016-11-22
EP2433953A4 (en) 2013-06-05
AU2010250452A1 (en) 2011-11-10
EP2433953A1 (en) 2012-03-28
CN102428096B (zh) 2015-03-25
KR101783291B1 (ko) 2017-09-29
WO2010134537A1 (ja) 2010-11-25
BRPI1008230A2 (pt) 2016-03-08
KR20120064650A (ko) 2012-06-19
PL2433953T3 (pl) 2015-12-31
JPWO2010134537A1 (ja) 2012-11-12

Similar Documents

Publication Publication Date Title
MX2011011960A (es) Peptidos penetradores de celulas.
NZ598356A (en) Antigenic tau peptides and uses thereof
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
IN2014CN02050A (es)
EP2573110A3 (en) Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
UA111141C2 (uk) Рекомбінантні антигени рсв
NZ600731A (en) Oxyntomodulin peptide analogue
MX2008009493A (es) Peptido novedoso y uso del mismo.
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
NZ600690A (en) Fkbp-l and uses thereof
NZ600732A (en) Oxyntomodulin peptide analogue
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
CO6362047A2 (es) Virus sincitial respiratorio vivo atenuado
NZ586074A (en) LCLRP peptides, constructs and uses thereof
WO2008113536A8 (en) Neurotrophic peptides
WO2010057242A3 (de) Vakzin
MX2009007261A (es) Vacuna de peptido foxp3.
WO2008113970A3 (en) Peptides
AR083766A1 (es) Peptido inmunogenico
MX2010005816A (es) Epítopos de péptido de stat3.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
MY151307A (en) Peptides having antimicrobial activity
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof
NZ603379A (en) Ect2 peptides and vaccines including the same

Legal Events

Date Code Title Description
FG Grant or registration